FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891839100> ?p ?o ?g. }

• W2891839100 endingPage "9046" @default.
• W2891839100 startingPage "9046" @default.
• W2891839100 abstract "9046 Background: The oral histone deacetylase inhibitor (HDACi) vorinostat (V) enhances tumor immunogenicity through several mechanisms and may augment response to PD-(L)1 blockade (IO). We report mature results from a phase I/Ib trial testing the combination of V with pembrolizumab (P) in mNSCLC. Methods: In phase I, pts with either IO-naïve or IO-pretreated mNSCLC were treated with P (200mg IV q3 wk) + V (200 or 400 mg PO daily). In phase Ib expansion, pts were required to have progressed on prior IO treatment. Primary endpoints were safety/tolerability; secondary endpoints included RR, PFS, DOR, and OS. Tissue and blood specimens from pre- and post-treatment were collected for correlative analyses to determine tumor gene expression changes, levels of myeloid-derived suppressor cells and changes in peripheral T-cell phenotype. Results: Between 3/2016 - 9/2017, Phase I: 14 pts were treated (4 at 200mg, and 10 at 400mg V dose); and Phase Ib: 20 pts were treated. Median age: 67 (range 38-82); Females: 11 (32%); ECOG 1: 32 (94%); and never/former/current smokers: 3/23/8 (9%/68%/23%). No DLTs were observed. The RP2D is P 200mg and V 400mg. Most common AE of any grade were fatigue (11%), anorexia (9%) and nausea/vomiting (8%). Most common G3 AE were myalgia, anemia and diarrhea. There were no G4/5 AEs. 3 (9%) pts had treatment discontinued due to toxicity. 30 pts are evaluable for response. PD-L1 expression was ≥ 1% in 18/30 (60%), and ≥ 50% in 11/30 (37%). 6 pts were IO-naïve and 24 IO-pretreated. 4 (13%) had PR (2 confirmed), 16 (53%) had SD, and 10 (33%) had PD for a disease control rate of 67%. In the IO-pretreated Ib cohort, 2 pts (1 confirmed; 1 pending repeat CT) had a PR and 10 had SD (8 confirmed). For IO-pretreated pts, mPFS was 3.2 months. For IO-naïve, mPFS was 7.6 months. Preliminary tumor RNA-seq studies showed increase in IFN gamma and HDACi target gene expression, including CXCL9. Conclusions: V + P was well tolerated. The combination demonstrates preliminary anti-tumor activity despite progression on prior IO treatment and gene expression changes consistent with mechanism of HDACi action. A randomized phase II portion of this study, examining P combined with V vs. placebo in immunotherapy naïve pts, is ongoing. Clinical trial information: NCT02638090." @default.
• W2891839100 created "2018-09-27" @default.
• W2891839100 creator A5000451156 @default.
• W2891839100 creator A5007121755 @default.
• W2891839100 creator A5022912407 @default.
• W2891839100 creator A5032171890 @default.
• W2891839100 creator A5036140702 @default.
• W2891839100 creator A5046273815 @default.
• W2891839100 creator A5054228821 @default.
• W2891839100 creator A5062655853 @default.
• W2891839100 creator A5063517617 @default.
• W2891839100 creator A5064494204 @default.
• W2891839100 creator A5064826649 @default.
• W2891839100 creator A5078661586 @default.
• W2891839100 creator A5090445265 @default.
• W2891839100 date "2018-05-20" @default.
• W2891839100 modified "2023-09-23" @default.
• W2891839100 title "Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC)." @default.
• W2891839100 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.9046" @default.
• W2891839100 hasPublicationYear "2018" @default.
• W2891839100 type Work @default.
• W2891839100 sameAs 2891839100 @default.
• W2891839100 citedByCount "7" @default.
• W2891839100 countsByYear W28918391002019 @default.
• W2891839100 countsByYear W28918391002020 @default.
• W2891839100 countsByYear W28918391002021 @default.
• W2891839100 countsByYear W28918391002023 @default.
• W2891839100 crossrefType "journal-article" @default.
• W2891839100 hasAuthorship W2891839100A5000451156 @default.
• W2891839100 hasAuthorship W2891839100A5007121755 @default.
• W2891839100 hasAuthorship W2891839100A5022912407 @default.
• W2891839100 hasAuthorship W2891839100A5032171890 @default.
• W2891839100 hasAuthorship W2891839100A5036140702 @default.
• W2891839100 hasAuthorship W2891839100A5046273815 @default.
• W2891839100 hasAuthorship W2891839100A5054228821 @default.
• W2891839100 hasAuthorship W2891839100A5062655853 @default.
• W2891839100 hasAuthorship W2891839100A5063517617 @default.
• W2891839100 hasAuthorship W2891839100A5064494204 @default.
• W2891839100 hasAuthorship W2891839100A5064826649 @default.
• W2891839100 hasAuthorship W2891839100A5078661586 @default.
• W2891839100 hasAuthorship W2891839100A5090445265 @default.
• W2891839100 hasConcept C104317684 @default.
• W2891839100 hasConcept C121608353 @default.
• W2891839100 hasConcept C126322002 @default.
• W2891839100 hasConcept C143998085 @default.
• W2891839100 hasConcept C185592680 @default.
• W2891839100 hasConcept C197934379 @default.
• W2891839100 hasConcept C203092338 @default.
• W2891839100 hasConcept C2776262904 @default.
• W2891839100 hasConcept C2777063308 @default.
• W2891839100 hasConcept C2777701055 @default.
• W2891839100 hasConcept C2778305200 @default.
• W2891839100 hasConcept C2778375690 @default.
• W2891839100 hasConcept C2778616394 @default.
• W2891839100 hasConcept C2780057760 @default.
• W2891839100 hasConcept C2780580376 @default.
• W2891839100 hasConcept C29730261 @default.
• W2891839100 hasConcept C31760486 @default.
• W2891839100 hasConcept C535046627 @default.
• W2891839100 hasConcept C55493867 @default.
• W2891839100 hasConcept C64927066 @default.
• W2891839100 hasConcept C71924100 @default.
• W2891839100 hasConcept C90924648 @default.
• W2891839100 hasConceptScore W2891839100C104317684 @default.
• W2891839100 hasConceptScore W2891839100C121608353 @default.
• W2891839100 hasConceptScore W2891839100C126322002 @default.
• W2891839100 hasConceptScore W2891839100C143998085 @default.
• W2891839100 hasConceptScore W2891839100C185592680 @default.
• W2891839100 hasConceptScore W2891839100C197934379 @default.
• W2891839100 hasConceptScore W2891839100C203092338 @default.
• W2891839100 hasConceptScore W2891839100C2776262904 @default.
• W2891839100 hasConceptScore W2891839100C2777063308 @default.
• W2891839100 hasConceptScore W2891839100C2777701055 @default.
• W2891839100 hasConceptScore W2891839100C2778305200 @default.
• W2891839100 hasConceptScore W2891839100C2778375690 @default.
• W2891839100 hasConceptScore W2891839100C2778616394 @default.
• W2891839100 hasConceptScore W2891839100C2780057760 @default.
• W2891839100 hasConceptScore W2891839100C2780580376 @default.
• W2891839100 hasConceptScore W2891839100C29730261 @default.
• W2891839100 hasConceptScore W2891839100C31760486 @default.
• W2891839100 hasConceptScore W2891839100C535046627 @default.
• W2891839100 hasConceptScore W2891839100C55493867 @default.
• W2891839100 hasConceptScore W2891839100C64927066 @default.
• W2891839100 hasConceptScore W2891839100C71924100 @default.
• W2891839100 hasConceptScore W2891839100C90924648 @default.
• W2891839100 hasIssue "15_suppl" @default.
• W2891839100 hasLocation W28918391001 @default.
• W2891839100 hasOpenAccess W2891839100 @default.
• W2891839100 hasPrimaryLocation W28918391001 @default.
• W2891839100 hasRelatedWork W1481779217 @default.
• W2891839100 hasRelatedWork W2035566433 @default.
• W2891839100 hasRelatedWork W2345585868 @default.
• W2891839100 hasRelatedWork W2571164384 @default.
• W2891839100 hasRelatedWork W2614458325 @default.
• W2891839100 hasRelatedWork W2892262919 @default.
• W2891839100 hasRelatedWork W2996891337 @default.
• W2891839100 hasRelatedWork W3177224496 @default.
• W2891839100 hasRelatedWork W3197516152 @default.

• next